Literature DB >> 25435209

Deal watch: Genentech dives deeper into the next wave of cancer immunotherapies.

Sarah Crunkhorn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25435209     DOI： 10.1038/nrd4502

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  1 in total

1.  The immune checkpoint inhibitors: where are we now?

Authors:  Rachel M Webster
Journal:  Nat Rev Drug Discov       Date:  2014-10-27       Impact factor: 84.694
  1 in total
  2 in total

1.  What is the tryptophan kynurenine pathway and why is it important to neurotherapeutics?

Authors:  Ian Davis; Aimin Liu
Journal:  Expert Rev Neurother       Date:  2015-05-24       Impact factor: 4.618

Review 2.  Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy.

Authors:  Kai Tang; Ya-Hong Wu; Yihui Song; Bin Yu
Journal:  J Hematol Oncol       Date:  2021-04-21       Impact factor: 17.388
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.